COPYRIGHT INFORMATION GOES ‌ONEGENE BIOTECHNOLOGY © 2016. ALL RIGHTS RESERVED

WHO WE ARE

Since its establishment in Suwon, Gyeonggi-do, Korea in 2016, Onegene Biotechnology has been developing the proprietary long-acting multi-ligand presenting platform that overcomes practical limitations in the development of therapeutics with more than three ligands. 
By its effective use, we develop multi-targeting therapeutics for complex diseases such as metabolic, inflammatory diseases, and cancer. We envision that our technology opens a new path in the treatment of complex chronic diseases.

PLATFORM

The Onegene Biotechnology's platform adopts an exceptionally efficient protein conjugation technology, which post-translationally connects two separately produced proteins.

Onegene’s robust post-translational fusion technology overcomes the fundamental issues in developing multi-targeting protein therapeutics such as intrinsic thermodynamic limitations, manufacturability challenges, and plug-and-play easiness.

CONTACT US

LOCATION

TEL.

+82-31-8014-2696

FAX.

+82-31-8014-2690

#204, Ace Gwanggyotower2,

91 Changnyong-daero 256beon-gil,

Yeongtong-gu, Suwon-si,
Gyeonggi-do, Republic of Korea